With unusual bipartisan support, a new piece of legislation of about 1,000 pages was signed into law on Dec. 13, 2016 – the 21st Century Cures Act. The Act will allocate about $6 billion to a variety of medically related needs. While the bill has received both applause and criticism from various interest groups, there are many relevant points to mention.
National Institutes of Health (NIH) Funding: The Act provides billions of dollars of new funding to the NIH for research into diseases such as cancer and Alzheimer’s.
Health Information Technology: Recognizing current IT challenges, the Act allows for reduction of some documentation burden and creates an electronic medical record (EMR) tool to assist with EMR-related decisions. In addition, it gives authority to the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) to investigate claims of IT sharing obstacles.
Site-of-Service Cost Disclosure: The Centers for Medicare & Medicaid Services (CMS) will create a website with a guide to estimate payment amounts for outpatient surgeries, along with the beneficiary’s liability amount.
Medicare Part A Inpatient/Part B Outpatient Surgical Code Comparator: This is a juxtaposition of the inpatient surgical codes to related outpatient codes for 10 common procedures.
Socio-Economic Status Adjustment for Readmissions: This is a risk adjustment calculation meant to account for various socio-economic factors, initially using a temporary method, but eventually requiring a permanent methodology.
Medicare Advantage for ESRD: This is an option for MA plan enrollment for ESRD patients as of 2021.
Opioid Abuse Prevention: Designates funds for opioid abuse prevention and therapy programs.
Ambulatory Surgical Center (ASC) MACRA Exclusion: Temporarily excludes providers that primarily practice in ASCs from Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Merit-Based Incentive Payment System (MIPS) requirements.
Telehealth: Requires CMS to provide information on expanding telehealth coverage, along with comparative information for commercial insurers.
“Breakthrough” Technologies and Combination Products: A program will be established for expediting approval for breakthrough technologies. Certain criteria will be put in place to determine validity of the “breakthrough” label. A dedicated center for combination products is to be created to streamline the review of new products.
Antimicrobial Stewardship: The Food and Drug Administration (FDA) shall continue to monitor antimicrobial resistance. For a serious or life-threatening infection, the FDA may approve a new agent in a limited patient cohort, even with a lack of evidence to establish a satisfactory benefit/harm ratio in a broader population.
Experience Data Gathering: Prior to granting approval, the FDA will be seeking broader input regarding the experience of patients, beyond that of just the manufacturer. The experience data can be derived from any person or entity.
Qualification of Drug Development Tools: Establishes a process for the qualification of new drug/biologic development tools. The purpose is to encourage the development of genetically targeted agents for rare diseases. It includes expansion of the process for grants and vouchers for priority review of drugs for such conditions.
Trial Design and Level of Evidence: The FDA will now consider inclusion of sources other than randomized controlled trials (RCTs) for new drug reviews. A new set of guidelines will be developed utilizing broad input from industry sources, academic institutions, professional societies, patient advocacy/consumer groups, disease research foundations, etc.
Patient Access to Therapies: Developers of investigational therapies for serious diseases will make available policies for inclusion of patients on a publicly accessible website. Applications for regenerative therapy, such as cell therapy and human cell/tissue products, will be eligible for an accelerated review.
While there is much to like in this Act, its fate is unknown with the new Trump administration having taken office. The changes to the FDA approval process should also scare the heck out of every doctor who is tired of the constant TV ads for medications for toenail fungus, lung cancer, and of course, erectile dysfunction.
While the president has been talking a lot about high drug prices, he is clearly pro-business and anti-regulation. The Act will allow drugs to be approved based on data other than controlled clinical trials, perhaps only requiring drug companies to prove safety with no requirement for efficacy data. Scary times could be ahead.
This month, the Secretary of the U.S. Department of Health and Human Services (HHS) – Robert F. Kennedy, Jr. – testified at seven congressional committee
I am having a disagreement with the Centers for Medicare & Medicaid Services (CMS) that is worth discussing. As I have been teaching for the
Please log in to your account to comment on this article.
Breast biopsy procedures may be clinically straightforward but accurately translating them into compliant billing can be anything but. In this focused webcast, Shawn Blackburn, CPC, CPMA, CIC, CRC, CCS-P breaks down how imaging guidance, lesion count, laterality, and payer expectations all impact how these procedures should be reported. Through clear explanations and real-world scenarios, you’ll gain practical insight into aligning clinical workflows with billing requirements, avoiding common pitfalls, and ensuring your documentation supports accurate reimbursement and compliance.
Gain clarity and confidence in OB‑GYN coding with this expert‑led webcast featuring Sherri L. Clayton, RHIT, CSS. You’ll learn how to apply global maternity package rules accurately, select the right CPT codes for procedures and visits, and identify documentation gaps that lead to denials. With practical guidance and real examples, this session helps you strengthen compliance, reduce audit risk, and ensure accurate reimbursement for women’s health services.
Uncover essential coding insights with nationally recognized coding authority Kay Piper, RHIA, CDIP, CCS. Through ICD10monitor’s interactive, on‑demand webcast series, Kay walks you through the AHA’s 2026 ICD‑10‑CM/PCS Quarterly Coding Clinics, translating each update into practical, easy‑to‑apply guidance designed to sharpen precision, ensure compliance, and strengthen day‑to‑day decision‑making. Available shortly after each official release.
Uncover critical guidance on the ICD-10-CM/PCS code updates. Kay Piper reviews and explains ICD-10-CM/PCS coding guidelines in the AHA’s fourth quarter 2026 ICD-10-CM/PCS Coding Clinic in an easy to access on-demand webcast.
Traditional utilization management models can no longer keep pace with regulatory shifts, payer scrutiny, and operational pressures. In this webcast, Tiffany Ferguson, LMSW, CMAC, ACM, ACPA-C, introduces an Adaptive Model strategy that modernizes UM through role specialization, technology-driven workflows, and proactive, team-based processes. Attendees will learn how to restructure programs to improve efficiency, strengthen clinical collaboration, and enhance financial performance in a rapidly changing healthcare environment.
Federal auditors are intensifying their focus on inpatient psychiatric facilities, using advanced data analytics to spotlight outliers and pursue high‑dollar repayments. In this high‑impact webcast, Michael Calahan, PA, MBA, Compliance Officer and V.P., Hospital & Physician Compliance, breaks down what regulators are really targeting in IPF-PPS admissions, documentation, treatment and discharge planning. Attendees will learn practical steps to tighten processes, avoid common audit triggers and protect reimbursement and reduce the risk of multimillion-dollar repayment demands.
In this timely session, Stacey Shillito, CDIP, CPMA, CCS, CCS-P, CPEDC, COPC, breaks down the complexities of Medical Decision Making (MDM) documentation so providers can confidently capture the true complexity of their care. Attendees will learn practical, efficient strategies to ensure documentation aligns with current E/M guidelines, supports accurate coding, and reduces audit risk, all without adding to charting time.
Join Ronald Hirsch, MD, FACP, CHCQM for The PEPPER Returns – Risk and Opportunity at Your Fingertips, a practical webcast that demystifies the PEPPER and shows you how to turn complex claims data into actionable insights. Dr. Hirsch will explain how to interpret key measures, identify compliance risks, uncover missed revenue opportunities, and understand new updates in the PEPPER, all to help your organization stay ahead of audits and use this powerful data proactively.
Celebrate Lab Week with MedLearn! Sign up to win one year of our Laboratory All Access Pass! Click here to learn more →
Have a Medicare regulation question you’d love Dr. Hirsch to answer? Now is your chance! CLICK HERE to learn more→
Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
